Starpharma Holdings Limited
SPHRF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | 0.08 | -0.00 | 0.19 |
| FCF Yield | -10.73% | -4.32% | -21.98% | 3.17% |
| EV / EBITDA | -7.04 | -5.54 | -3.12 | -13.95 |
| Quality | ||||
| ROIC | -48.29% | -45.55% | -45.26% | 9.59% |
| Gross Margin | -42.97% | -93.04% | -201.62% | 89.30% |
| Cash Conversion Ratio | 1.04 | 0.37 | 1.27 | -2.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.71% | 11.99% | 10.62% | 5.61% |
| Free Cash Flow Growth | -135.52% | 77.86% | -538.25% | 124.26% |
| Safety | ||||
| Net Debt / EBITDA | 2.91 | 3.39 | 2.84 | 10.95 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.56 | 2.01 | 2.17 | 0.28 |
| Cash Conversion Cycle | 108.53 | 55.50 | 324.17 | -246.39 |